[go: up one dir, main page]

WO2015116729A3 - Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders - Google Patents

Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders Download PDF

Info

Publication number
WO2015116729A3
WO2015116729A3 PCT/US2015/013367 US2015013367W WO2015116729A3 WO 2015116729 A3 WO2015116729 A3 WO 2015116729A3 US 2015013367 W US2015013367 W US 2015013367W WO 2015116729 A3 WO2015116729 A3 WO 2015116729A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
disorders
treatment
combination therapy
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/013367
Other languages
French (fr)
Other versions
WO2015116729A2 (en
Inventor
Scott STROMATT
Brian Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptevo Research and Development LLC
Original Assignee
Emergent Product Development Seattle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Development Seattle LLC filed Critical Emergent Product Development Seattle LLC
Publication of WO2015116729A2 publication Critical patent/WO2015116729A2/en
Publication of WO2015116729A3 publication Critical patent/WO2015116729A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods of treating a patient with a B-cell malignancy or disorder comprising administering an anti-CD37 antibody or antibody fragment in combination with an anti-CD20 antibody or antibody fragment. In one embodiment, the invention provides methods for B-cell reduction comprising contacting B-cells with an anti-CD37 antibody or antibody fragment and an anti-CD20 antibody or antibody fragment. The invention includes compositions and kits comprising anti-CD37 antibody and antibody fragments for use in combination with an anti-CD20 antibody or antibody fragment. The methods and compositions of the invention may further include a BCR antagonist such as a SYK inhibitor, a BTK inhibitor, a PI3K inhibitor, or a CXCR4 antagonist.
PCT/US2015/013367 2014-01-28 2015-01-28 Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders Ceased WO2015116729A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461932518P 2014-01-28 2014-01-28
US61/932,518 2014-01-28
US201462088179P 2014-12-05 2014-12-05
US62/088,179 2014-12-05

Publications (2)

Publication Number Publication Date
WO2015116729A2 WO2015116729A2 (en) 2015-08-06
WO2015116729A3 true WO2015116729A3 (en) 2015-11-05

Family

ID=53757910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/013367 Ceased WO2015116729A2 (en) 2014-01-28 2015-01-28 Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders

Country Status (1)

Country Link
WO (1) WO2015116729A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202001677QA (en) 2010-03-12 2020-04-29 Debiopharm International S A Cd37-binding molecules and immunoconjugates thereof
SG193447A1 (en) 2011-04-01 2013-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP6979877B2 (en) 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． Combination of anti-CD37 immunoconjugate and anti-CD20 antibody
MX2018002467A (en) * 2015-08-28 2018-06-15 Debiopharm Int Sa Antibodies and assays for detection of cd37.
US11278629B2 (en) * 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
JP2021525735A (en) 2018-05-30 2021-09-27 デビオファーム インターナショナル， エス． アー． Anti-CD37 immunoconjugate dosing regimen
EP3810194A1 (en) * 2018-06-22 2021-04-28 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
BR112022018235A2 (en) 2020-03-12 2022-12-20 Rigel Pharmaceuticals Inc METHOD OF TREATMENT, METHOD OF TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, METHOD OF INHIBITING A CYTOKINE RESPONSE IN A PATIENT, METHOD OF TREATMENT OF ACUTE KIDNEY INJURY AND METHOD OF TREATMENT OF THROMBOSIS
WO2021183790A1 (en) * 2020-03-12 2021-09-16 Rigel Pharmaceuticals, Inc. Method for treatment of covid-19-associated conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135900A1 (en) * 2008-11-13 2010-06-03 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
US8333966B2 (en) * 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
WO2013090478A1 (en) * 2011-12-12 2013-06-20 Pikamab, Inc Predicting responsiveness to antibody maintenance therapy
US20130309224A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab
US20140377258A1 (en) * 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333966B2 (en) * 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US20100135900A1 (en) * 2008-11-13 2010-06-03 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
WO2013090478A1 (en) * 2011-12-12 2013-06-20 Pikamab, Inc Predicting responsiveness to antibody maintenance therapy
US20130309224A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab
US20140377258A1 (en) * 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators

Also Published As

Publication number Publication date
WO2015116729A2 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2015116729A3 (en) Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
MA39906A (en) Combination therapies for the treatment of cancer
PH12017501857B1 (en) Pd-l1 antagonist combination treatments
MX2016015181A (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
MX2018012493A (en) Methods for monitoring and treating cancer.
EP4585273A3 (en) Mechanism of resistance to bet bromodomain inhibitors
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MD20160007A2 (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
BR112017023517A2 (en) anti-cd20 antibody for cancer treatment, pharmaceutical composition, method of treating a cancer patient and use of an anti-cd20 antibody
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL247586A0 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
WO2017143115A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
HK1252514A1 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
SMT202300244T1 (en) Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer
NZ779615A (en) Semaphorin-4d antagonists for use in cancer therapy
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
HK40097436A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15743852

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15743852

Country of ref document: EP

Kind code of ref document: A2